RELAPSED/REFRACTORY B-CELL LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could an AI-Designed pill take on Hard-to-Treat cancers?
Disease control Recruiting nowThis early-stage trial is testing an experimental oral drug called ISM8207 in people with advanced solid tumors or relapsed/refractory B-cell lymphoma who have no standard treatment options left. The main goals are to check the drug's safety, tolerability, and how the body proces…
Matched conditions: RELAPSED/REFRACTORY B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New hope for tough lymphomas: experimental drug STP938 enters human trials
Disease control Recruiting nowThis study is for adults with B-cell or T-cell lymphoma that has returned or stopped responding to at least two prior treatments. The drug, STP938, blocks a protein cancer cells need to grow. The trial has two parts: first, finding a safe dose (Phase 1), then testing how well it …
Matched conditions: RELAPSED/REFRACTORY B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Step Pharma, SAS • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on tough lymphoma
Disease control Recruiting nowThis study is testing a new type of cell therapy called CD19/CD20 CAR/TRuC-T for people with B-cell lymphoma that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and attack cance…
Matched conditions: RELAPSED/REFRACTORY B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen University General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New CAR-T therapy targets tough blood cancers in early trial
Disease control Recruiting nowThis study tests a new treatment called BAFFR CAR-T for people with B-cell blood cancers that have returned or not responded to standard therapy. The therapy uses a patient's own immune cells, modified to attack cancer cells. The goal is to see if it is safe and helps control the…
Matched conditions: RELAPSED/REFRACTORY B-CELL LYMPHOMA
Phase: NA • Sponsor: Donghua Zhang • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New cancer drug BR111 enters first human tests
Disease control Recruiting nowThis early-stage trial is testing a new drug, BR111, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug might slow or shrink tum…
Matched conditions: RELAPSED/REFRACTORY B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Can a simple test predict CAR t success? new study hopes to find out
Knowledge-focused Recruiting nowThis study is testing a new combination of blood tests, scans, and health checks to see if it can predict which lymphoma patients will respond well to CAR T cell therapy. Researchers will follow 50 patients with relapsed or hard-to-treat B-cell lymphoma who are already scheduled …
Matched conditions: RELAPSED/REFRACTORY B-CELL LYMPHOMA
Sponsor: University of Zurich • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC